Previous 10 | Next 10 |
Marinus Pharmaceuticals ( NASDAQ: MRNS ) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in ...
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older ZTALMY One™ offers comprehensive patient services, including access and prescription drug support Marinus Pharmaceuticals , In...
Theravance Biopharma ( TBPH ) +14% to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B. TransGlobe Energy ( TGA ) +9% agrees to acquire TransGlobe Energy in all stock deal. Payoneer Global ( PAYO ) +8% . Marinus Pharm...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) is selling its rare pediatric disease Priority Review Voucher (PRV) for $110M. The Radnor, Pa.-based company had received the voucher when the U.S. Food and Drug Administration (FDA) approved its seizure treatment Ztalmy in M...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial ...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase 3 RAISE trial in refractory status epilepticus (RSE) to expand e...
The U.S.-based commercial-stage company Marinus Pharmaceuticals (NASDAQ:MRNS) announced on Wednesday that the European regulators agreed to the company’s request to allow additional four months to submit data for the review of its seizure candidate ganaxolone. In 2021, Marinus (MRNS) s...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June: Citi B...
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2022 Earnings Conference Call May 12, 2022, 04:00 PM ET Company Participants Sasha Damouni Ellis - VP, Corporate Communications, and IR Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Steve Pfanstiel - Chief Financial Offi...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...